Phase I dose-escalation study of docetaxel, nedaplatin, and 5-fluorouracil combination chemotherapy in patients with advanced esophageal cancer

详细信息    查看全文

• 作者：Tatsuya Miyazaki (1)
  Makoto Sohda (1)
  Naritaka Tanaka (1)
  Shigemasa Suzuki (1)
  Keisuke Ieta (1)
  Makoto Sakai (1)
  Akihiko Sano (1)
  Takehiko Yokobori (1)
  Takanori Inose (1)
  Masanobu Nakajima (2)
  Minoru Fukuchi (1)
  Hitoshi Ojima (1)
  Hiroyuki Kato (2)
  Hiroyuki Kuwano (1)
  
• 关键词：Docetaxel ; Nedaplatin ; 5 ; Fluorouracil ; Chemotherapy ; Esophageal cancer
• 刊名：Cancer Chemotherapy and Pharmacology
• 出版年：2013
• 出版时间：April 2013
• 年：2013
• 卷：71
• 期：4
• 页码：853-857
• 全文大小：160KB
• 参考文献：1. Ajani JA, Ryan B, Rich TA, McMurtrey M, Roth JA, DeCaro L, Levin B, Mountain C (1992) Prolonged chemotherapy for localised squamous carcinoma of the oesophagus. Eur J Cancer 28A:880-84 CrossRef
  2. Hilgenberg AD, Carey RW, Wilkins EW Jr, Choi NC, Mathisen DJ, Grillo HC (1988) Preoperative chemotherapy, surgical resection, and selective postoperative therapy for squamous cell carcinoma of the esophagus. Ann Thorac Surg 45:357-63 CrossRef
  3. Iizuka T, Kakegawa T, Ide H, Ando N, Watanabe H, Tanaka O, Takagi I, Isono K, Ishida K, Arimori M et al (1992) Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japanese Esophageal Oncology Group Trial. Jpn J Clin Oncol 22:172-76
  4. Osaka Y, Shinohara M, Hoshino S, Ogata T, Takagi Y, Tsuchida A, Aoki T (2011) Phase II study of combined chemotherapy with docetaxel, CDDP and 5-FU for highly advanced esophageal cancer. Anticancer Res 31:633-38
  5. Kato H, Fukuchi M, Manda R, Nakajima M, Miyazaki T, Sohda M, Masuda N, Fukai Y, Tsukada K, Kuwano H (2003) Efficacy and toxicity of nedaplatin and 5-FU with radiation treatment for advanced esophageal carcinomas. Anticancer Res 23:3493-498
  6. Akutsu Y, Shuto K, Kono T, Uesato M, Hoshino I, Shiratori T, Miyazawa Y, Isozaki Y, Akanuma N, Matsubara H (2012) A phase I/II study of second-line chemotherapy with fractionated docetaxel and nedaplatin for 5-FU/cisplatin-resistant esophageal squamous cell carcinoma. Hepatogastroenterology 59(119). doi:10.5754/hge11952
  7. Guo JF, Zhang B, Wu F, Wang B, Xing H, Zhu GY, Nie XY, Peng J (2010) A phase II trial of docetaxel plus nedaplatin and 5-fluorouracil in treating advanced esophageal carcinoma. Chin J Cancer 29:321-24 CrossRef
  8. Muro K, Hamaguchi T, Ohtsu A, Boku N, Chin K, Hyodo I, Fujita H, Takiyama W, Ohtsu T (2004) A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol 15:955-59 CrossRef
  9. Ajani JA (2002) Docetaxel for gastric and esophageal carcinomas. Oncology (Williston Park) 16:89-6
  10. Lorch JH, Goloubeva O, Haddad RI, Cullen K, Sarlis N, Tishler R, Tan M, Fasciano J, Sammartino DE, Posner MR (2011) Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol 12:153-59 CrossRef
  11. Yokota T, Hatooka S, Ura T, Abe T, Takahari D, Shitara K, Nomura M, Kondo C, Mizota A, Yatabe Y, Shinoda M, Muro K (2011) Docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline-resectable T4 esophageal cancer. Anticancer Res 31:3535-541
  12. Eisterer W, De Vries A, Kendler D, Spechtenhauser B, Konigsrainer A, Nehoda H, Virgolini I, Lukas P, Bechter O, Woll E, Ofner D (2011) Triple induction chemotherapy and chemoradiotherapy for locally advanced esophageal cancer. A phase II study. Anticancer Res 31:4407-412
  13. Yamasaki M, Miyata H, Tanaka K, Shiraishi O, Motoori M, Peng YF, Yasuda T, Yano M, Shiozaki H, Mori M, Doki Y (2011) Multicenter phase I/II study of docetaxel, cisplatin and fluorouracil combination chemotherapy in patients with advanced or recurrent squamous cell carcinoma of the esophagus. Oncology 80:307-13 CrossRef
  14. Tanaka T, Fujita H, Sueyoshi S, Tanaka Y, Sasahara H, Mori N, Nagano T, Yamana H, Shirouzu K (2007) Second-line combination chemotherapy with docetaxel for cisplatin-pretreated refractory metastatic esophageal cancer: a preliminary report of initial experience. Chemotherapy 53:449-53 CrossRef
  15. Sasaki Y, Tamura T, Eguchi K, Shinkai T, Fujiwara Y, Fukuda M, Ohe Y, Bungo M, Horichi N, Niimi S et al (1989) Pharmacokinetics of (glycolate-0,0--diammine platinum (II), a new platinum derivative, in comparison with cisplatin and carboplatin. Cancer Chemother Pharmacol 23:243-46 CrossRef
  16. Suzumura Y, Kato T, Ueda R, Ota K (1989) Effect of treatment schedule on antitumor activity of glycolate-0,0-diammineplatinum(II), a new platinum derivative: comparison with cis-diamminedichloroplatinum(II). Anticancer Res 9:1083-088
  17. Sasaki Y, Fukuda M, Morita M, Shinkai T, Eguchi K, Tamura T, Ohe Y, Yamada K, Kojima A, Nakagawa K et al (1990) Prediction from creatinine clearance of thrombocytopenia and recommended dose in patients receiving (glycolato-O,O--diammine platinum (II) (NSC 375101D). Jpn J Cancer Res 81:196-00 CrossRef
  18. Fukuda M, Shinkai T, Eguchi K, Sasaki Y, Tamura T, Ohe Y, Kojima A, Oshita F, Hara K, Saijo N (1990) Phase II study of (glycolate-O,O- diammineplatinum(II), a novel platinum complex, in the treatment of non-small-cell lung cancer. Cancer Chemother Pharmacol 26:393-96 CrossRef
  19. Akaza H, Togashi M, Nishio Y, Miki T, Kotake T, Matsumura Y, Yoshida O, Aso Y (1992) Phase II study of cis-diammine(glycolato)platinum, 254-S, in patients with advanced germ-cell testicular cancer, prostatic cancer, and transitional-cell carcinoma of the urinary tract. 254-S Urological Cancer Study Group. Cancer Chemother Pharmacol 31:187-92 CrossRef
  20. Minamide J, Aoyama N, Takada K, Oota Y (2007) Evaluation of docetaxel, CDDP and 5-FU combined therapy as second-line chemotherapy for esophagus cancer. Gan To Kagaku Ryoho 34:49-2
  21. Tanaka Y, Yoshida K, Osada S, Yamaguchi K, Takahashi T (2011) Docetaxel, nedaplatin, and S-1 (DGS) chemotherapy for advanced esophageal carcinoma: a phase I dose-escalation study. Anticancer Res 31:4589-597
  
• 作者单位：Tatsuya Miyazaki (1)
  Makoto Sohda (1)
  Naritaka Tanaka (1)
  Shigemasa Suzuki (1)
  Keisuke Ieta (1)
  Makoto Sakai (1)
  Akihiko Sano (1)
  Takehiko Yokobori (1)
  Takanori Inose (1)
  Masanobu Nakajima (2)
  Minoru Fukuchi (1)
  Hitoshi Ojima (1)
  Hiroyuki Kato (2)
  Hiroyuki Kuwano (1)
  
  1. Department of General Surgical Science (Surgery 1), Gunma University Graduate School, 3-39-22, Showa-machi, Maebashi, Gunma, 371-8511, Japan
  2. First Department of Surgery, Dokkyo Medical University, Tochigi, Japan
  
• ISSN：1432-0843

文摘

More effective protocols are needed for unresectable and recurrent esophageal cancer. Therefore, we conducted a phase I trial to establish the recommended dose of docetaxel, nedaplatin, and 5-fluorouracil (DNF) as combination chemotherapy. Fourteen patients with esophageal cancer were enrolled and received DNF combination therapy at different dose levels according to the treatment and examination plan. Dose-limiting toxicities (DLTs) included febrile neutropenia. DLTs occurred in 3/5 patients at level 4. The recommended doses (level 3) of DNF were 60?mg/m2 (day 1), 70?mg/m2 (day 1), and 700?mg/m2 (days 1-), respectively, given at 3-week intervals. In conclusion, DNF combined chemotherapy for advanced esophageal cancer was associated with relatively minor adverse events and was safely administered at the recommended dose. A phase II study is now underway.